logo
Plus   Neg
Share
Email

Seattle: TUKYSA Approved In Switzerland To Treat HER2-positive Breast Cancer

Seattle Genetics, Inc. (SGEN) announced the Swiss Agency for Therapeutic Products has granted approval for TUKYSA tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer. The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. FDA Oncology Center of Excellence.

On April 17, the FDA approved TUKYSA in the U.S. under the FDA's Real-Time Oncology Review pilot program, and represented the first new drug approved under Project Orbis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT